Healthy Extracts Expects Record Sales for Q2 2025, Driving Strong Positive Adj. EBITDA
Healthy Extracts (OTCQB:HYEX), a nutraceutical company, reported preliminary Q2 2025 results with expected record net revenue exceeding $970,000, up 8% year-over-year. The company anticipates adjusted EBITDA of nearly $100,000, driven by strong marketing and distribution performance.
Key highlights include a 107% increase in Amazon "Subscribe & Save" customers and 88% growth in Direct-to-Consumer subscriptions. The company launched three new product formulations in sleep and gut health categories, maintaining its top three Amazon ranking. HYEX also established an exclusive logistics agreement with Gelteq for North America.
Management increased 2025 revenue guidance to $4.2 million, representing 34% growth over 2024, supported by new product launches and expanding market channels.
Healthy Extracts (OTCQB:HYEX), un'azienda nutraceutica, ha riportato risultati preliminari del secondo trimestre 2025 con un fatturato netto record previsto superiore a 970.000 $, in crescita dell'8% rispetto all'anno precedente. L'azienda prevede un EBITDA rettificato di quasi 100.000 $, trainato da solide performance di marketing e distribuzione.
I punti salienti includono un aumento del 107% dei clienti Amazon "Subscribe & Save" e una crescita dell'88% negli abbonamenti Direct-to-Consumer. L'azienda ha lanciato tre nuove formulazioni di prodotti nelle categorie del sonno e della salute intestinale, mantenendo la sua posizione tra i primi tre su Amazon. HYEX ha inoltre stipulato un accordo logistico esclusivo con Gelteq per il Nord America.
La direzione ha rivisto al rialzo la previsione di fatturato per il 2025 a 4,2 milioni di dollari, con una crescita del 34% rispetto al 2024, supportata dal lancio di nuovi prodotti e dall'espansione dei canali di mercato.
Healthy Extracts (OTCQB:HYEX), una empresa nutracéutica, informó resultados preliminares del segundo trimestre de 2025 con ingresos netos récord esperados que superan los 970,000 $, un aumento del 8% interanual. La compañía anticipa un EBITDA ajustado de casi 100,000 $, impulsado por un sólido desempeño en marketing y distribución.
Los aspectos destacados incluyen un aumento del 107% en clientes de Amazon "Subscribe & Save" y un crecimiento del 88% en suscripciones Direct-to-Consumer. La empresa lanzó tres nuevas formulaciones de productos en las categorías de sueño y salud intestinal, manteniendo su posición entre los tres primeros en Amazon. HYEX también estableció un acuerdo logístico exclusivo con Gelteq para Norteamérica.
La dirección aumentó la previsión de ingresos para 2025 a 4.2 millones de dólares, lo que representa un crecimiento del 34% respecto a 2024, respaldado por nuevos lanzamientos de productos y la expansión de canales de mercado.
Healthy Extracts (OTCQB:HYEX)는 뉴트라슈티컬 회사로서 2025년 2분기 예비 실적을 발표했으며, 순매출은 전년 대비 8% 증가한 970,000달러를 넘어 사상 최고치를 기록할 것으로 예상됩니다. 회사는 강력한 마케팅 및 유통 성과에 힘입어 조정 EBITDA가 거의 100,000달러에 이를 것으로 전망하고 있습니다.
주요 내용으로는 아마존 'Subscribe & Save' 고객이 107% 증가했고, 직접 소비자 대상 구독자 수가 88% 성장한 점이 있습니다. 회사는 수면 및 장 건강 카테고리에서 세 가지 신제품 포뮬레이션을 출시하며 아마존 상위 3위권을 유지했습니다. 또한 HYEX는 북미 지역을 위한 Gelteq와 독점 물류 계약을 체결했습니다.
경영진은 2025년 매출 전망치를 420만 달러로 상향 조정했으며, 이는 2024년 대비 34% 성장한 수치로, 신제품 출시와 시장 채널 확장에 힘입은 결과입니다.
Healthy Extracts (OTCQB:HYEX), une entreprise nutraceutique, a publié des résultats préliminaires pour le deuxième trimestre 2025 avec un chiffre d'affaires net record attendu dépassant 970 000 $, en hausse de 8 % par rapport à l'année précédente. La société anticipe un EBITDA ajusté d'environ 100 000 $, soutenu par de solides performances en marketing et distribution.
Les points clés incluent une augmentation de 107 % des clients Amazon "Subscribe & Save" et une croissance de 88 % des abonnements Direct-to-Consumer. La société a lancé trois nouvelles formulations de produits dans les catégories sommeil et santé intestinale, conservant sa place dans le top trois sur Amazon. HYEX a également conclu un accord logistique exclusif avec Gelteq pour l'Amérique du Nord.
La direction a relevé ses prévisions de chiffre d'affaires pour 2025 à 4,2 millions de dollars, représentant une croissance de 34 % par rapport à 2024, soutenue par le lancement de nouveaux produits et l'expansion des canaux de marché.
Healthy Extracts (OTCQB:HYEX), ein Nutraceutical-Unternehmen, meldete vorläufige Ergebnisse für das zweite Quartal 2025 mit einem erwarteten Rekordumsatz von über 970.000 $, was einem Anstieg von 8 % gegenüber dem Vorjahr entspricht. Das Unternehmen erwartet ein bereinigtes EBITDA von fast 100.000 $, angetrieben durch starke Marketing- und Vertriebsleistungen.
Wichtige Highlights sind ein 107%iger Anstieg der Amazon "Subscribe & Save"-Kunden und ein 88%iges Wachstum bei Direktabonnements. Das Unternehmen brachte drei neue Produktformulierungen in den Kategorien Schlaf und Darmgesundheit auf den Markt und hält weiterhin einen Platz unter den Top drei bei Amazon. HYEX schloss zudem einen exklusiven Logistikvertrag mit Gelteq für Nordamerika ab.
Das Management hob die Umsatzprognose für 2025 auf 4,2 Millionen Dollar an, was einem Wachstum von 34 % gegenüber 2024 entspricht, unterstützt durch neue Produkteinführungen und die Erweiterung der Vertriebskanäle.
- Record revenue for three consecutive quarters with Q2 2025 reaching $970,000
- Strong subscription growth with 107% increase in Amazon customers and 88% in DTC
- Positive adjusted EBITDA of nearly $100,000 in Q2 2025
- Expanded product portfolio with three new formulations in sleep and gut health
- Secured exclusive North American logistics agreement with Gelteq
- Increased 2025 revenue guidance to $4.2 million (34% growth)
- Maintaining high gross margins across product lines
- Results are preliminary and unaudited, subject to revision
- Operating on OTCQB market rather than major exchange
Q2 2025 adjusted EBIDTA at nearly
$100,000 , demonstrating strong leverage in the company's marketing and distribution channel platform.Subscription-based recurring revenue continues to drive strong positive cash flow with more than
107% increase from Amazon "Subscribe & Save" customers and88% increase in DTC subscription customers.Continued market and product line expansion keeping performance on track for another record second half and full year; maintaining guidance of
34% net revenue growth in 2025.
LAS VEGAS, NEVADA / ACCESS Newswire / July 22, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in research-based nutraceuticals for transformational health and longevity, reported preliminary unaudited results for the second quarter ended June 30, 2025. All comparisons are to the same year-ago period unless otherwise noted.
Second quarter 2025 net revenue is expected to exceed a record
Adjusted EBIDTA in the second quarter is expected to total nearly
Amazon "Subscribe & Save" customers increased
"We have now achieved record-setting revenue for three consecutive quarters as our growth strategies continue to bear fruit," commented Healthy Extracts president, Duke Pitts. "These results once again demonstrate our strengthening performance across our direct-to-consumer and retail channels for both our traditional and new product offerings."
"We also maintained our top three Amazon ranking in our category, with this due to our well-tuned marketing strategies," continued Pitts. "These strategies are supported by unique formulations and range of delivery systems that our customers find exceptionally beneficial for their heart and brain health-and now also for their sleep and gut health."
As the result of years of research and development, Healthy Extracts recently launched three new product formulations representing new product categories that include sleep and gut health. The company has been able to successfully cross-promote these products across multiple sales channels. The new products position the company for substantial revenue growth and profitability over the coming quarters.
"We plan to drive future growth by launching additional products and new categories in the current third quarter," noted Pitts. "This includes a new oral delivery system based on exclusive IP provided by Gelteq (NASDAQ:GELS), with whom we also recently established an exclusive logistics and distribution agreement for North America."
Healthy Extracts' heart heath unit, Bergamet NA, recently introduced two new products, with the company's major brand ambassador, Whitney Johns, also launching several-all which premiered during this summer's Amazon Prime Day:
Revolutionary heart health formulation, STAT10: Targets an unmet need of more than 40 million statin users in the U.S. featuring CoQ10, Berberine and Citrus Bergamot SuperFruit™.
Science-based healthy sleep formulation, 4Sleep: Natural sleep supplement specially designed to support deeper, more restorative rest.
Whitney Johns Gut Health Straw: Exclusive technology that delivers up to 4 grams of prebiotic fiber and 60B CFUs of probiotic. This new oral delivery technology will be featured in other new products to be launched in 2025.
The new Healthy Extracts products based on a second exclusive delivery system from GelTeq include:
MYNUS: Unique sugar blocker formulation designed to reduce up to
42% of the sugar impact from meals. MYNUS on-the-go gel-packs will be offered under the company's exclusive U.S. and Canadian licensing and manufacturing agreement with Gelteq.Hydrate EZ: Convenient on-the-go gel pack specially formulated to provide hydration, focus, recovery, and sleep benefits without the need for mixing.
"We believe our product innovation and well-tuned systems for customer engagement and retention has continued to differentiate our brands from the competition," said Pitts. "Given the strong leverage we have created in our business model, we see these new products each generating on their own millions in additional annual revenues and at our traditional high gross margins."
"Our solid cash flow and favorable capitalization structure also enables us to pursue opportunistic M&A opportunities, particularly those that provide exclusive IP that would differentiate us from our industry peers. Overall, we believe we remain well positioned for another year of record growth in revenues, cash flow and shareholder value."
Pitts discussed the company's M&A activity, which currently include multiple target candidates, in a video interview recently posted to the company's YouTube channel here.
2025 Outlook
Based upon the strong revenue performance in the first half of 2025 and better forward visibility, the company recently increased its outlook for total net revenue for the full year of 2025 to more than
New product launches across new categories and formats which are scheduled for the year are expected to drive this growth with greater profitability (excluding non-cash-based expenses).
The new products are expected to benefit from the broad market channels the company has strategically developed and invested in over the last several years. The company plans to drive future growth by reinvesting its profits into new product development and channel expansion.
The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its quarterly results in August.
About Healthy Extracts "Live Life Young Again"
Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals.
The company's subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids.
UBN's KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2025, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food & Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™
Use of Non-GAAP Measures
This press release contains financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which are EBITDA and adjusted EBITDA. EBITDA is defined for the purposes of this press release as net income before Income tax expense, Interest expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA excluding the gain or loss related to stock-based option/warrant expense, change in fair value of derivative, and offering costs.
Healthy Extracts' management believes that EBITDA and adjusted EBITDA are useful supplemental measures of our operating performance and provide our investors meaningful measures of overall corporate performance. EBITDA is also presented because management believes that it is frequently used by investment analysts, investors, and other interested parties as a measure of financial performance. Adjusted EBITDA is also presented because management believes that it provides our investors additional measures of our core business. However, non-GAAP measures do not have a standardized meaning prescribed by GAAP, and investors are cautioned that non-GAAP measures, such as EBITDA and adjusted EBITDA, should not be construed as an alternative to net income or loss or other income statement data (which are determined in accordance with GAAP) as an indicator of our performance or as a measure of liquidity and cash flows. Management's method of calculating EBITDA and adjusted EBITDA may differ materially from the method used by other companies and, accordingly, may not be comparable to similarly titled measures used by other companies. The Company plans to provide a reconciliation of EBITDA and adjusted EBITDA to net income, the most comparable GAAP measure, in its full results for the second quarter of 2025 to be issued in August.
Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact
Investor Contact
CMA Investor Relations
Tel (949) 432-7554
Email contact
SOURCE: HEALTHY EXTRACTS INC.
View the original press release on ACCESS Newswire
FAQ
What were Healthy Extracts (HYEX) Q2 2025 revenue and EBITDA results?
How much did HYEX's subscription customer base grow in Q2 2025?
What is Healthy Extracts' revenue guidance for 2025?
What new products did Healthy Extracts launch in Q2 2025?
What is HYEX's partnership with Gelteq?
